|
Session 75
Poster Abstracts
Immune Activation and Lymphocyte Function
Tuesday, 1-4 pm
Room: Hall D |
443
 |
A Threshold of Partial CD4+ T Cell Restoration in GALT Is Sufficient for Developing Multi-functional Anti-HIV CD8+T Cell Responses and Control of Mucosal Immune Activation and Viral Suppression in HIV-infected Patients Receiving HAART
Monica Macal*1, S Sankaran1, T W Chun2, E Reay1, J Flamm3, T Prindiville1, and S Dandekar1
1Univ of California, Davis, US; 2Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US; and 3Kaiser Permanente Med Group, Sacramento, CA, US |
444
|
HIV Infection Leads to Increased Immune Activation by 2 Distinct Pathways that Differentially Affect CD4 and CD8 T Cells
Marta Catalfamo*1, M Di Mascio2, Z Hu2, S Srinivasula3, V Thaker1, J Adelsberger3, A Rupert3, M Baseler3, G Roby1, and C Lane1
1Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US; 2NIAID, NIH, Bethesda, MD, US; and 3SAIC-Frederick, MD, US |
| 445 |
Abnormal T Cell Phenotypes Persist Despite Effective HAART
Brinda Emu*1,2, S Deeks1, W Moretto2, R Hoh1, J Martin1,3, D Nixon2, and J McCune2
1Positive Hlth Prgm, Univ of California, San Francisco, US; 2Univ of California, San Francisco, US; and 3Univ of California, San Francisco, US |
446
|
Enfuvirtide Therapy Increases Naïve and Central Memory CD4 T Cells, Decreases the Level of Immune Activation and Apoptosis
H Carsenti Dellamonica1, J Durant1, M Ticchioni2, F Guillouet de Salvador1, J Dufayard Cottalorda3, R Garraffo4, Pierre Dellamonica*1, and M Gougeon5
1Hosp Archet Hosp, Nice, France; 2Hosp Archet, Nice, France; 3Hosp Archet, Nice, France; 4Ctr Hosp Univ Necker, Paris, France; and 5Pasteur Inst, Paris, France |
447
|
Dual Function of the Inhibitory Co-receptor PD-1 as a Marker for Activated and Functionally Impaired T Cells in SIV-infected Rhesus Macaques
Nadine Salisch*1,2, A Awad1, D Evans1, and P Johnson1,3
1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US; 2Univ Erlangen-Nuremberg, Erlangen, Germany; and 3Massachusetts Gen Hosp, Boston, US |
448
|
CXCR4 Receptor Expression Is More Common on Activated CD4+ T Cells than CCR5 Expression in HIV-1 Infection
Frederick Hecht*1,2,3, E Sinclair4, A Carrico5, P Moran1,3, P Hunt1,2, M Killian1, P Bacchetti6, T Ho4, S Folkman1,3, and S Deeks1,2
1Univ of California, San Francisco, US; 2Univ of California, San Francisco, US; 3Univ of California, San Francisco Osher Ctr for Integrative Med, US; 4Univ of California, San Francisco Core Immunology Lab, US; 5Univ of California, San Francisco, US; and 6Univ of California, San Francisco, US |
449
|
Phenotypic and Functional Characterization of the Thymus in HIV-infected Patients
Alessandra Bandera*1, G Ferrario2, M Saresella3, I Marventano3, G Marchetti4, D Trabattoni5, L Gazzola4, M Clerici5, and A Gori1
1San Gerardo Hosp, Univ of Milan-Bicocca, Monza, Italy; 2Luigi Sacco Hosp, Univ of Milan, Italy; 3Don Carlo Gnocchi Fndn, Milan, Italy; 4San Paolo Hosp, Univ of Milan Med Sch, Italy; and 5Univ of Milan Med Sch, Italy |
450
|
Common Markers of T Cell Activation Do Not Indicate Markedly Higher Levels of HIV Infection of CD4+ T Cells in the Peripheral Circulation
Joe Casazza*, S Adzaku, D Ambrozak, D Douek, M Roederer, and R Koup
Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US |
451
|
Persistent PD-1 Expression Is Correlated with Poor Immune Recovery in HAART-treated HIV-1-infected Patients
Katharina Pfistershammer* and N Kohrgruber
Med Univ Vienna, Ausria |
452
|
HIV-1-infected Patients with Full Suppression of Viral Replication but Impaired Recovery of CD4 Cells Display Immune Activation with Decreased CD28 Expression and IL-10 Production
Christian Erikstrup*1,2, N Lohse3,4, S Ostrowski5, J Gerstoft6, G Kronborg4,7, and H Ullum1
1Rigshospitalet, Copenhagen, Denmark; 2Skejby Sygehus, Aarhus Univ Hosp, Denmark; 3Arhus Univ Hosp, Denmark; 4Danish HIV Cohort Study, Copenhagen Univ Hosp; 5Rigshospitalet and Faculty of Hlth Sci, Univ of Copenhagen, Denmark; 6Rigshospitalet, Copenhagen, Denmark; and 7Copenhagen Univ Hosp, Hvidovre, Denmark |
453
|
Marginal Zone B Cell Memory Populations Are Irreversibly Depleted in Pediatric HIV
Marianne Jacobsen*1, R Thiebaut2, C Fisher3, D Sefe1, M Clapson3, N Klein1, and H Baxendale1
1Inst of Child Hlth, London, UK; 2INSERM, Bordeaux, France; and 3Great Ormond St Hosp for Children, London, UK |
454
|
Abnormal Activation of the JAK/STAT Pathway in CD4+ T Cells of HIV-infected Patients (ANRS EP33 Study)
Olivier Juffroy*1, F Bugault1, O Lambotte2, J P Viard3, L Niel4, A Danckaert5, J F Delfraissy2, J Theze1, and L Chakrabarti1
1Pasteur Inst, Paris, France; 2Ctr Hosp Univ Bicetre, France; 3Hosp Necker, Paris, France; 4Hosp Percy, Clamart, France; and 5Pasteur Inst, Paris, France |
455
|
Potential Pre-treatment Interruption Immunological Predictors for CD4 Count Change Off Therapy in Chronically HIV-infected Subjects Having Various Pre-Treatment Interruption Viral Loads
Kenneth Huang*1, S Boulet1, C Tsoukas1, M Loutfy2, and N Bernard1
1Res Inst of the McGill Univ Hlth Care Ctr, Montreal, Canada and 2Univ of Toronto, Canada |
456
|
Effects of Timing of Processing and Lymphocyte Isolation on Detection of CD31 Expression on Naive CD4 T Cells in HIV-infected Patients
Jeanette Higgins*1, M Proschan2, J Metcalf2, R Stevens1, M Baseler1, C Lane2, and I Sereti2
1SAIC-Frederick, MD, US and 2NIH, Bethesda, MD, US |
457a
|
High-level Persistence of HIV Antigen-specific CD4+ T Cells in Untreated Chronic Infection, Detected by a Novel Flow Cytometric Assay
John Zaunders*1, S Pett2, M Bailey2, N Seddiki2, M Munier2, S Ip2, M Kim3, A Cunningham3, D Cooper1,2, and A Kelleher1,2
1Ctr for Immunology, St Vincent`s Hosp, Darlinghurst, Australia; 2Natl Ctr in HIV Epi and Clin Res, Univ of New South Wales, Australia; and 3Westmead Millenium Inst, Sydney, Australia |
457b
|
Combined Effects of Interleukin-10 and PD-1 on Virus-specific CD4 T Cell Proliferation during Chronic HIV-1 Infection
Mark Brockman*, D Kwon, D Tighe, S Le Gall, F Pereyra, B Walker, and D Kaufmann
Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US |
|
